文献速递肥胖与代谢综合征性腺与生殖内分泌

奥利司他对接受IVF-ET的超重或肥胖女性活产率的影响:一项随机临床试验

Effect of Orlistat on Live Birth Rate in Overweight or Obese Women Undergoing IVF-ET: A Randomized Clinical Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2021-01-01

该随机双盲安慰剂对照试验纳入877例BMI≥25的不孕女性,比较IVF-ET前4-12周奥利司他或安慰剂的疗效。

要点

  • IVF-ET前奥利司他减重未提高超重或肥胖女性的活产率。
  • 奥利司他组体重下降幅度显著大于安慰剂组。
  • 奥利司他组单胎出生体重显著高于安慰剂组。

核心结论

  • IVF-ET前奥利司他治疗未改善超重或肥胖女性的活产率,但有助于减重。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在中国19个生殖医学中心开展,2017年7月至2019年1月。
  • 共877例计划行IVF且BMI≥25的不孕女性,随机分为奥利司他组(n=439)和安慰剂组(n=438),治疗4至12周。
  • 主要结局为新鲜胚胎移植后的活产率。

主要发现

  • 两组在受孕率、临床妊娠率或流产率方面无显著差异。

临床怎么用

  • 对于接受IVF-ET的超重或肥胖女性,奥利司他减重干预不应以改善活产率为目的。
  • 奥利司他可考虑用于减重,但需权衡其对活产率无改善的预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Obesity management prior to infertility treatment remains a challenge. To date, results from randomized clinical trials involving weight loss by lifestyle interventions have shown no evidence of improved live birth rate. OBJECTIVE: This work aimed to determine whether pharmacologic weight-loss intervention before in vitro fertilization and embryo transfer (IVF-ET) can improve live birth rate among overweight or obese women. METHODS: We conducted a randomized, double-blinded, placebo-controlled trial across 19 reproductive medical centers in China, from July 2017 to January 2019. A total of 877 infertile women scheduled for IVF who had a body mass index of 25 or greater were randomly assigned to receive orlistat (n = 439) or placebo (n = 438) treatment for 4 to 12 weeks. The main outcome measurement was the live birth rate after fresh ET. RESULTS: The live birth rate was not significantly different between the 2 groups (112 of 439 [25.5%] with orlistat and 112 of 438 [25.6%] with placebo; P = .984). No significant differences existed between the groups as to the rates of conception, clinical pregnancy, or pregnancy loss. A statistically significant increase in singleton birth weight was observed after orlistat treatment (3487.50 g vs 3285.17 g in the placebo group; P = .039). The mean change in body weight during the intervention was -2.49 kg in the orlistat group, as compared to -1.22 kg in the placebo group, with a significant difference (P = .005). CONCLUSION: Orlistat treatment, prior to IVF-ET, did not improve the live birth rate among overweight or obese women, although it was beneficial for weight reduction.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Wang Z, Zhao J, Ma X, et al. Effect of Orlistat on Live Birth Rate in Overweight or Obese Women Undergoing IVF-ET: A Randomized Clinical Trial. J Clin Endocrinol Metab. 2021. PMID: 33991186. doi:10.1210/clinem/dgab340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。